Forty Seven

About:

Forty Seven is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways.

Website: http://www.fortyseveninc.com

Top Investors: Wellington Management, Lightspeed Venture Partners, Sutter Hill Ventures, Google Ventures, Clarus Ventures

Description:

Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways based on technology licensed from Stanford University. Forty Seven's lead program, 5F9, is a monoclonal antibody against the CD47 receptor, a "don't eat me" signal that cancer cells commandeer to avoid being ingested by macrophages. This antibody is currently being evaluated in six clinical studies in patients with solid tumors, acute myeloid leukemia, non-Hodgkin's lymphoma and colorectal carcinoma.